Can an ADC move from metastatic benefit into curative-intent early breast cancer? At #ESMO26, TALENT (LBA23) will test neoadjuvant trastuzumab deruxtecan in HER2-low / HR+ early breast cancer-with or without anastrozole, or sequenced with chemotherapy. The real question: activity is not enough. How should we weigh efficacy, ILD risk, and treatment positioning in early disease? Presenter: Sara Hurvitz #bcsm